Michael G. Goggins, MD

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine.Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017).Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018 and 2019, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries.

Neurologist Ashley Paul specializes in movement disorders and also serves as a clinician educator.Dr. Paul has expertise in Parkinson's Disease, atypical parkinsonism, tremors, chorea, dystonia, ataxia, restless leg syndrome, rapid eye movement sleep behavioral disorders, periodic limb movement of sleep and deep brain stimulation. She offers botulinum toxin injections for the treatment of dystonia.

Dr. Ankur Butala specializes in the care of persons with complex neuropsychiatric conditions, including persons with advanced Parkinson Disease or other movement or neurodegenerative disorders. Upon graduating from a selective Physician-Scientist program at Albany Medical College, he joined the University of Massachusetts in an uncommon residency in both Neurology and Psychiatry. Dual-trained neuropsychiatrists such as Dr. Butala have experience with: Parkinson Disease and atypical Parkinsonism, Huntington Disease, Ataxia, Dystonia, early-onset dementia, traumatic brain injury and chronic traumatic encephalopathy, autism spectrum disorders, medication refractory mood and psychotic disorders, epilepsy and functional neurological disorders. In residency, he developed an interest in circuit models of brain function and how non-pharmacological approaches such as Neuromodulation and brain stimulation may be used to address treatment-resistant conditions. Consequently, he joined Johns Hopkins University School of Medicine as a Clinical and Research Fellow from 2015 to 2018, where he developed a skill set including deep brain stimulation, non-invasive brain stimulation (tDCS), and measurement of eye movements.Currently, Dr. Butala's clinical and research interests are in diagnosing and managing persons with advanced Parkinson's Disease, movement disorders, and neuropsychiatric conditions using neuromodulation, cannabinoids, and entheogens. He has ongoing multidisciplinary collaborations with colleagues at the Whiting School of Engineering - Center of Speech & Language Processing in using Machine-Learning Models and Artificial Intelligence to improve the detection and diagnosis of Movement and Neuropsychiatric disorders.